ANN ARBOR, Mich., May 10, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (AMEX:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that it will hold its 1st
quarter 2011 investor conference call on Tuesday, May 17, 2011, at
1:00pm EDT. James S. Kuo, M.D., M.B.A., Adeona’s Chief Executive
Officer, will host the call.
The Company will be joined by special guest, Rhonda Voskuhl,
M.D., Director, University of California, Los Angeles (UCLA)
Multiple Sclerosis Program, UCLA Department of Neurology, and Lead
Principal Investigator of the multi-center clinical trial
evaluating Adeona’s Trimesta™ (oral estriol) drug candidate
for multiple sclerosis (MS) in women. Dr. Voskuhl is the
investigator who discovered that the female sex hormone, estriol,
could suppress MS-like symptoms in a mouse model of the disease.
This preclinical research led to a 10-patient clinical study
that showed an 82% decrease in brain lesions over a six month
period. This clinical study was followed by a 150-patient,
randomized, double-blind, placebo-controlled clinical trial of
Trimesta that is currently underway at 15 centers in the United
States. Dr. Voskuhl’s preclinical and clinical work has been
scientifically reviewed and awarded over $8 million in grant
funding by organizations such as the National Institutes of Health,
the National Multiple Sclerosis Society and other third party
groups. In addition to providing an update of the Trimesta clinical
trial, Dr. Voskuhl will share insights into her proposed new
mechanism to treat MS patients and will take questions about her
research.
Interested parties should call toll free 1-800-860-2442
(U.S.) or 1-866-605-3852 (Canada), or from outside North America +1
412-858-4600, fifteen minutes before the start of the call to
register and identify themselves as registra
‘/>”/>
SOURCE
